IPP Bureau
Govt. issues draft amendment to remove cough syrups from Schedule K
By IPP Bureau - January 01, 2026
Once finalized, cough syrups will no longer be available for over-the-counter sale
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
By IPP Bureau - December 31, 2025
The funding will accelerate Sinopia’s data-driven drug discovery efforts
GenSight Biologics gets early access nod for candidate gene therapy in Israel
By IPP Bureau - December 31, 2025
Applications include detailed scientific rationale and supporting clinical evidence
UK’s healthcare regulator warns against dangerous online weight-loss drugs
By IPP Bureau - December 31, 2025
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Shenzhen Biopharma leader Lu Xianping wins EY Entrepreneur Of The Year 2025 award
By IPP Bureau - December 31, 2025
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers
By IPP Bureau - December 31, 2025
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Azenta to sell B Medical Systems for $63 million
By IPP Bureau - December 31, 2025
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance
By IPP Bureau - December 31, 2025
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
By IPP Bureau - December 31, 2025
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Kokilaben Dhirubhai Ambani Hospital makes history with India’s first intercontinental remote robotic surgeries
By IPP Bureau - December 31, 2025
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Cupid to set up FMCG manufacturing facility in Saudi Arabia
By IPP Bureau - December 30, 2025
The plant is expected to enhance regional supply capabilities
Astal signs LoI with Immuna Therapeutics
By IPP Bureau - December 30, 2025
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
By IPP Bureau - December 30, 2025
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
By IPP Bureau - December 30, 2025
The study met its primary endpoint with flying colors
Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
By IPP Bureau - December 30, 2025
The partnership also sets the stage for broader collaboration on rare disease treatments
